MIRA Pharmaceuticals (NASDAQ: MIRA) highlights SKNY-1 preclinical obesity and nicotine data
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
MIRA Pharmaceuticals filed an 8-K to highlight new preclinical data on SKNY-1, its investigational oral drug candidate for obesity and nicotine addiction. A peer-reviewed manuscript in the International Journal of Molecular Sciences describes SKNY-1’s pharmacology and effects in an MC4R-deficient zebrafish obesity model.
The study reports that oral SKNY-1 produced dose-dependent weight loss over six days, including about a 30% reduction in body weight from baseline in the higher-dose group, with no significant reduction in whole-body density. It also details improvements in cholesterol measures, liver triglycerides, appetite-related gene expression, and compulsive feeding and nicotine-seeking behaviors.
The company emphasizes these findings are from zebrafish and in vitro systems only. SKNY-1 is not FDA approved, and its safety and efficacy in humans are not established.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Weight reduction at higher SKNY-1 dose: approximately 30% reduction in body weight
Treatment duration: six days
Journal reference: MDPI IJMS 27(10):4321
3 metrics
Weight reduction at higher SKNY-1 dose
approximately 30% reduction in body weight
Higher-dose zebrafish group after six days of oral treatment
Treatment duration
six days
Oral SKNY-1 administration period in zebrafish study
Journal reference
MDPI IJMS 27(10):4321
Publication citation for SKNY-1 zebrafish manuscript
Key Terms
cannabinoid receptor 1 (CB1), cannabinoid receptor 2 (CB2), monoamine oxidase B (MAO-B), MC4R-deficient zebrafish model, +1 more
5 terms
cannabinoid receptor 1 (CB1) medical
"SKNY-1 demonstrated differential engagement of cannabinoid receptor 1 (CB1) signaling pathways"
Cannabinoid receptor 1 (CB1) is a protein on cells, especially in the brain and nervous system, that acts like a lock for cannabis-like chemicals and naturally produced signals; when activated it influences appetite, pain, mood and memory. Investors track CB1 because it is a major drug target—therapies that block or stimulate it can create new treatments but also carry safety and regulatory risks, so trial results and patents materially affect company value.
cannabinoid receptor 2 (CB2) medical
"partial agonist activity at cannabinoid receptor 2 (CB2)"
Cannabinoid receptor 2 (CB2) is a protein found mainly on immune cells that acts like a lock on the cell surface, responding to natural or drug-made molecules to change how the cell behaves. Investors watch CB2 because it is a common drug target for treatments aimed at inflammation, pain and immune-related diseases; success or failure in developing CB2-targeting drugs can strongly affect a company’s clinical prospects, regulatory risk and potential market value.
monoamine oxidase B (MAO-B) medical
"selective in vitro inhibition of monoamine oxidase B (MAO-B) relative to MAO-A"
Monoamine oxidase B (MAO-B) is an enzyme in the brain and other tissues that breaks down certain mood- and movement-related chemicals, including dopamine. For investors, MAO-B matters because medicines that block or alter its activity are common drug targets for neurological conditions; successful inhibitors can drive prescription sales but also carry safety and interaction risks that affect regulatory approval, commercial value, and patent economics.
MC4R-deficient zebrafish model medical
"in an MC4R-deficient zebrafish model exhibiting obesity-associated metabolic and reward-related phenotypes"
leptin and ghrelin gene expression medical
"modulation of leptin and ghrelin gene expression patterns"
FAQ
What did MIRA (MIRA) disclose about SKNY-1 in this 8-K filing?
MIRA reported a peer-reviewed publication on SKNY-1, its investigational oral drug for obesity and nicotine addiction. The study in zebrafish showed weight loss, metabolic improvements, and behavioral effects, but SKNY-1 remains preclinical and unproven in humans.
What preclinical weight loss results did SKNY-1 show for MIRA (MIRA)?
The zebrafish study found oral SKNY-1 led to dose-dependent weight loss over six days, including about a 30% body weight reduction at a higher dose. These results are limited to an MC4R-deficient zebrafish obesity model, not human patients.
How did SKNY-1 affect cholesterol and liver fat in MIRA (MIRA) research?
The publication reports SKNY-1 normalized total cholesterol and LDL, increased HDL, and reduced hepatic triglyceride accumulation in the zebrafish obesity model. These metabolic changes were observed only in preclinical animal testing and do not demonstrate human benefit.
Is SKNY-1 approved by the FDA according to MIRA (MIRA)?
No. The filing states SKNY-1 has not been approved by the U.S. Food and Drug Administration for any indication. Its safety and efficacy have not been established in humans, and current evidence comes from zebrafish and in vitro experiments.
Where can investors read the SKNY-1 manuscript mentioned by MIRA (MIRA)?
The company notes the SKNY-1 paper is available online in the International Journal of Molecular Sciences, published by MDPI. The filing provides a direct URL to the article for readers who want full experimental details and data tables.